Clinical trial · no report yet · Phase 1
NCT04557150
A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)
- NCT04557150 ↗
- Completed
- Hoffmann-La Roche
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Multicenter, Phase I Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig (RO7425781) in Participants With Relapsed or Refractory Multiple Myeloma
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Forimtamig
- Arms
- Part I: Dose Escalation · Experimental
- Part II: Dose Expansion · Experimental
- Enrollment
- 225
- Primary outcomes
- Percentage of Participants with Adverse Events (AEs)
- Percentage of Participants with Dose Limiting Toxicities (DLTs)
- Sponsor
- Hoffmann-La Roche
- Start
- Nov 11, 2020
- Primary completion
- Mar 17, 2026
- Results posted
- No
- Registry record
- NCT04557150 · updated Apr 13, 2026
Publications
linked from the registry- Kraft TE, Marrer-Berger E, Belli S, Haegel H, Schneider A, Giusti AM, Bscheider M, Jacob W, Weisser M, Blanco L, Frances N, Rossmann E, Steiner G, Azpiroz AZ, Paiva B, Martinet L, Fauti T. Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple Myeloma. Clin Pharmacol Ther. 2026 Sep;120(3):745-752. doi: 10.1002/cpt.70366. Epub 2026 Jun 17. PubMed 42310437
- Eckmann J, Fauti T, Biehl M, Zabaleta A, Blanco L, Lelios I, Gottwald S, Rae R, Lechner S, Bayer C, Dekempe Q, Osl F, Carrie N, Kassem S, Lorenz S, Christopeit T, Carpy A, Bujotzek A, Broske AM, Dekhtiarenko I, Attig J, Kunz L, Cremasco F, Adelfio R, Fertig G, Dengl S, Gassner C, Bormann F, Kirstenpfad C, Kraft T, Diggelmann S, Knobloch M, Hage C, Feddersen R, Heidkamp G, Poschinger T, Mayoux M, Bernasconi L, Prosper F, Dumontet C, Martinet L, Leclair S, Xu W, Paiva B, Klein C, Umana P. Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2+1 format, for the treatment of multiple myeloma. Blood. 2025 Jan 9;145(2):202-219. doi: 10.1182/blood.2024025987. PubMed 39476124